Janux Therapeutics (NASDAQ:JANX) Receives Outperform Rating from Wedbush

Wedbush reaffirmed their outperform rating on shares of Janux Therapeutics (NASDAQ:JANX - Free Report) in a research report released on Friday,RTT News reports. The firm currently has a $76.00 target price on the stock, up from their prior target price of $75.00.

A number of other equities analysts have also recently weighed in on JANX. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research note on Friday, December 27th. William Blair restated an "outperform" rating on shares of Janux Therapeutics in a research note on Friday, January 10th. HC Wainwright boosted their price target on shares of Janux Therapeutics from $63.00 to $70.00 and gave the company a "buy" rating in a report on Tuesday, December 3rd. BTIG Research boosted their price objective on Janux Therapeutics from $82.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. Finally, Scotiabank lifted their price target on shares of Janux Therapeutics from $42.00 to $62.00 and gave the stock a "sector perform" rating in a research report on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Janux Therapeutics currently has an average rating of "Buy" and a consensus target price of $88.00.

Remove Ads

Janux Therapeutics Stock Performance

Shares of JANX stock traded down $1.84 during midday trading on Friday, reaching $29.99. 1,772,594 shares of the company were exchanged, compared to its average volume of 1,039,414. The company's 50 day moving average price is $43.25 and its two-hundred day moving average price is $47.86. The company has a market cap of $1.57 billion, a P/E ratio of -25.63 and a beta of 3.16. Janux Therapeutics has a 12 month low of $29.63 and a 12 month high of $71.71.

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The company reported ($0.36) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. As a group, sell-side analysts predict that Janux Therapeutics will post -1.38 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now directly owns 82,139 shares in the company, valued at approximately $4,507,788.32. The trade was a 13.97 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO David Alan Campbell sold 5,000 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $60.00, for a total value of $300,000.00. Following the sale, the chief executive officer now directly owns 293,054 shares in the company, valued at $17,583,240. This represents a 1.68 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,668 shares of company stock valued at $2,577,515. 29.40% of the stock is owned by insiders.

Institutional Trading of Janux Therapeutics

A number of institutional investors have recently modified their holdings of the stock. Plato Investment Management Ltd boosted its stake in Janux Therapeutics by 18.7% in the third quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock valued at $54,000 after buying an additional 187 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in shares of Janux Therapeutics by 77.7% during the fourth quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock valued at $54,000 after purchasing an additional 442 shares in the last quarter. GF Fund Management CO. LTD. bought a new stake in shares of Janux Therapeutics during the fourth quarter worth about $59,000. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Janux Therapeutics by 21.9% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock valued at $87,000 after buying an additional 339 shares during the period. Finally, Avanza Fonder AB bought a new position in Janux Therapeutics in the 4th quarter valued at approximately $139,000. 75.39% of the stock is currently owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.